

Inside

Introduction
Annual Wellness Visits via Telehealth
Clinical Staff Role
Physician/APP Role page 5
Addendum A: Billing Guidance
Addendum B: Health Risk Assessment
Addendum C: Preventive Screening Schedule Form
Addendum D: Adult Preventive Health Care Schedule: Recommendations from the USPSTF



Introduction

Established in 2010 through the Affordable Care Act, Annual Wellness Visits were designed to encourage monitoring of physical and cognitive abilities, as well as development of plans associated with lessening the impact of increasing frailty on everyday life for elders. Several of the chronic conditions experienced by elders are typically not of acute onset. These conditions often display minor symptoms at earlier stages that may be missed if not specifically screened.

The Annual Wellness Visit is each provider's opportunity to spend focused time with their patients and

- Perform a health risk assessment
- Close "gaps in care" for immunizations, depression screening, fall risk, and other screenings
- Review the patient's chronic conditions and form an agreed-upon plan including treatment goals for the coming year
- Assure appropriate HCC coding of all chronic conditions.

During the COVID-19 outbreak, CMS placed Annual Wellness Visits on the list of approved services that can be administered via telehealth (cms.gov/newsroom/fact-sheets/medicaretelemedicine-health-care-provider-fact-sheet).

The aim of this document is to help providers transition from in-person AWVs to telehealth visits. This document provides standard screening guidelines, portions may need to be adapted based on guidance by your local quality committee.

Annual Wellness Visits via Telehealth

Please note that Welcome to Medicare Visits (G0402) are NOT covered via Telehealth

Billable codes: G0438 (Initial AWV) or G0439 (Subsequent AWV)

Services can be completed by real-time audio/video communication or telephonically

Items that can be completed by clinical staff (MA, RN, etc.)

- Obtain and document patient verbal consent
- · Document modality of visit (Zoom, Skype, etc.)
- Preventive screening schedule form (Addendum C)
 - Complete form to be scanned into AEHR
- Health risk assessment (HRA) form
 - Complete questionnaire with patient to be scanned into AEHR
- · Reconcile medications, confirm with provider
- Obtain and document vitals provided by patient
 - Height (documented "as stated by patient")
 - Weight (documented "as stated by patient")
 - BMI calculation based on vitals provided by patient
 - Blood pressure (if patient not able to provide via home device, document why "unable to obtain due to telehealth restrictions")
- · Review and document patient medical, social, family histories

Items that can be completed by physician or APP

- Complete HPI (CHI initial/subsequent Medicare Annual Wellness Assessment template in AEHR)
 - Behavioral risk factors
 - Diet
 - Self-assessment of health status
 - Psychosocial risk factors
 - Functional ability and level of safety
 - List patient's providers/suppliers
 - Preventive services
 - » Review preventive screening schedule form with patient and offer copy be mailed to patient
 - Administer preferred cognitive assessment tool (MMSE, MiniCog, etc.)
 - Advance directive planning
 - » If appropriate and patient agrees to discuss, may also bill ACP via telehealth
 - 16-45 minutes of ACP discussion CPT 99497 (include time in note)
 - 46+ minutes of ACP discussion CPT 99498 (include time in note)
- · Document review of systems
- · Please note that a physical exam is NOT required
- Document assessment plan discussion/summary

Clinical Staff Role

Remember a Welcome to Medicare visit is done the first year they are on Medicare Part B We are unable to do Welcome to Medicare visits via Telehealth as it requires obtaining visual acuity and an EKG

- The clinical staff will fill out the preventive screening form for provider (Addendum C).
- Medications and allergies will be reconciled.
- · Clinical staff can ask if the patient has the equipment at home to complete any vitals. If they are able to report, input as below.
 - If your EHR has a discreet field for home vital signs, input patient-reported vitals.
 - If not, vitals should be entered as text or as patient-reported in notes.
 - Do not enter under vitals tab.
- · The clinical staff can discuss advance directives with the patient if they would like to discuss it. Please notify PCP when they take over to discuss.
- If physician/APP is working with clinical staff, the staff will schedule the mammograms, bone density, AAA; after the physician/APP reviews the completed preventive screening form (Addendum C) with patient and determines what needs to be ordered. Otherwise, the physician/APP will place orders to be deferred until the fall.
- The clinical staff will request records needed to update CQS.
 - Update immunizations in EHR; if patient refuses yearly influenza vaccines, the clinical staff will document that.
- The clinical staff will collect educational materials, such as fall prevention, Coloquard, BMI, and/or smoking cessation cards with information for scheduled appointments and a copy of the preventive screening form and prepare all to mail to patient.

Tips to help determine eligibility:

- · Look in EHR to determine date of last AWV.
 - If prior screening was a Welcome to Medicare visit, patient is due for an initial screening.
 - If prior screening was an initial or subsequent screening, patient will be due for a subsequent screening.
- If patient has not had a prior Medicare Annual Wellness Visit, Part B start date can be viewed in the practice management system.
 - If the patient has supplement insurance, the nurse can look in the practice management system to determine when it became effective.
 - » Remember a Welcome to Medicare visit is done the first year they are on Medicare Part B. We do not schedule these patients for a telehealth visit, as a visual acuity and EKG is needed during the Welcome to Medicare exam.

Physician/APP* Role

Remember a Welcome to Medicare exam is done the first year they are on Medicare Part B We are unable to do Welcome to Medicare visits via Telehealth as it requires obtaining visual acuity and an EKG.

- Review the health risk assessment (Addendum B) questions and questions entered in daily note (AWV note in EHR) that has been completed by clinical staff.
- · Discuss any pertinent positives found that have not already been addressed with clinical staff
 - For example, discuss fall prevention if fall risk is positive.
- · Review the preventive screening schedule form (Addendum C) that has been completed by the clinical staff and discuss what is due for the patient.
 - Lung cancer screening shared decision-making can be done and billed for during this visit.
 - » If preventative screenings require separate appointments, consider scheduling them in the fall.
 - Any clinical testing needed (AAA screening, mammograms, Dexa scans, etc.) can and should be ordered during AWV visit if due.
 - » Clinical staff is able to schedule these at time of AWV if order is placed. If clinical staff that is assisting provider with AWV is unable to schedule the patient at time of visit, use current office process for deferred orders.
 - Only Medicare is covering diabetic educator telehealth visits at this time. Need to clarify if all patients with AWV are eligible, if supplementary insurance makes a difference, etc.
- · Discuss with the patient goals for care and management of risk factors and chronic disease (based on the assessment), discuss and document patient plan for health management.
- · Physician/APP can also bill for advanced care planning (ACP) if at least 16 minutes was spent discussing advanced directives.
 - Advance care planning (ACP) is the face-to-face time a physician or other qualified health care professional spends with a patient, family member, or surrogate to explain and discuss advance directives.
- · Physician/APP should document in the discussion/summary what is due, what has been ordered and what has been addressed.

^{*}Distant site practitioners who can furnish and get payment for covered telehealth services (subject to state law) can include physicians, nurse practitioners, physician assistants, nurse midwives, certified nurse anesthetists, clinical psychologists, clinical social workers, registered dietitians, and nutrition professionals.

Addendum A

Billing Guidance

- · Who is eligible for these visits:
 - Medicare covers an AWV for beneficiaries who are no longer within 12 months of the effective date of their first Medicare Part B coverage period
 - Patients who have not received an IPPE or an AWV providing PPPS within the past 12 months
- Initial AWV is performed the first year after the IPPE and coded as G0438, with DX code Z00.00 (general adult medical examination without abnormal findings) or Z00.01 (general adult medical examination with abnormal findings)
 - Subsequent AWV is performed every year thereafter and is coded as G0439, with DX code Z00.00 or Z00.01
- Patients' chronic diseases should be listed and coded according to HCC hierarchical coding.
- AWV requirements: documentation must include all 10 of the following elements to be considered billable:
 - 1 Health risk assessment
 - 2 Establishment of a current list of providers and suppliers
 - 3 Review of medical and family history
 - 4 Measurement of height, weight, BMI, and blood pressure (document: if there is a caregiver available or if patient knows weight, temperature, BP - if patient has a BP monitor; document what you can and keep in mind that a more detailed exam may be necessary in the future)
 - 5 Review of potential risk factors for depression and other mood disorders
 - 6 Review of functional ability and level of safety
 - 7 Detection of any cognitive impairment the patient may have
 - 8 Establishment of a written screening schedule (such as a checklist)
 - 9 Establishment of a list of risk factors
 - 10 Provision of personalized health advice and referral to appropriate health education or other preventive services

IPPE and AWV Billing			
Initial Preventative Physical Exam (IPPE) Cannot be done via telehealth Billing code: G0402 ICD-10: Z00.00 – Normal findings Z00.01 – Abnormal findings Depression screening: Z13.89 Reimbursement: \$150 (2013)	First Annual Wellness Visit (AWV) Billing code: G0438 ICD-10: Z00.00 – Normal findings Z00.01 – Abnormal findings Depression screening: Z13.89 Reimbursement: \$170	Subsequent AWVs Billing code: G0439 ICD-10: Z00.00 – Normal findings Z00.01 – Abnormal findings Depression screening: Z13.89 Reimbursement: \$110	
Eligibility			
Within the first 12 months of Medicare Part B eligibility	After 12 months of Part B eligibility and more than 12 months since an IPPE (This is a once per lifetime service)	Every year after the first AWV (each AWV must be 11 full months after the month of the last AWV)	
Provider			
Physician or qualified non-physician practitioner (physician assistant, nurse practitioner, or clinical nurse specialist)	Same as IPPE requirements or by a medical professional (including a health educator, registered dietitian, nutrition professional, or other licensed practitioner) or a team of medical professionals who are working under the direct supervision of a physician		

Addendum B

If available, use EHR Health Risk Assessment structured tool instead

Date of service:	Patient	t name:	DOB:
Member ID#:	Plan na	ame:	
Patient information / Den	nographic data		
Age / Gender A	ge:	MaleFemale	
		or Alaska Native Asian Black or African America or other Pacific Islander White: indicate if Hispan	
Self-assessment - Health	n status		
Health risk assessment		Response	Document recommendations given to patient
In general, compared to or age, would you say that yo		☐ Poor ☐ Fair ☐ Good ☐ Very good ☐ Excellent	
Do you have any concerns health and conditions?	s about your	Yes No If yes, what are they?	
Have you been diagnosed chronic medical condition	•	Yes No If yes, indicate condition: □ Diabetes □ Hypertension □ Heart Disease □ Heart failure □ Coronary artery disease □ COPD □ Asthma □ Arthritis / Location □ Other	
Have you had any surgerie	es?	Yes No If yes, what surgeries?	
Have any close family mediagnosed with a serious i		Yes No If yes, which illness?	
Have you had a flu shot?		Yes No If yes, date & location	
Have you had a pneumon	ia shot?	Yes No If yes, date & location	
Self-assessment - Falls			
In the past 12 months, hav more times?	e you fallen 2 or	Yes No If yes, date & location	
Are you afraid that you mi of walking or balance prob		☐Yes ☐No	
Self-assessment – Activiti	ies of daily living (A	ADL)	
In the past 7 days, did you others to perform everyda such as eating, getting dre bathing, walking, or using	ay activities essed, grooming,	☐ Yes ☐ No (If yes, indicate all that apply from list in first column)	
In the past 7 days, did you from others to take care of as laundry and housekeep shopping, using the teleptopreparation, transportation your own medications?	of things such bing, banking, hone, food	☐ Yes ☐ No (If yes, indicate all that apply from list in first column)	

Health Risk Assessment (HRA) for Use with Annual Wellness Visits

ALL FIELDS REQUIRED

Addendum B: Health Risk Assessment (continued)

Self-assessment - Nutrition		
Over the past 7 days, how many times did you eat fast food or snacks or pizza?	□0 □1 □2 □3 or more	
Over the past 7 days, how many servings of fruits or vegetables did you eat each day?	□ 0 □ 1 □ 2 □ 3 or more	
Over the past 7 days, how many sodas and sugar sweetened drinks (regular, not diet) did you drink each day?	□ 0 □ 1 □ 2 □ 3 or more	
Self-assessment - Medication		
How often do you have trouble taking medicines the way you have been told to take them?	☐ I do not have to take medicine ☐ I always take them as prescribed ☐ Sometimes I take them as prescribed ☐ I seldom take them as prescribed	
Do you have any questions about your medications?	Yes No If yes, what are they	
Self-assessment – Oral health / Hearing / S	leep / Physical activity	
How would you describe the condition of your mouth and teeth, including false teeth and dentures?	☐ Excellent ☐ Very good ☐ Good ☐ Fair ☐ Poor	
Do you have problems with your hearing?	☐ Yes ☐ No ☐ Sometimes	
Do you snore or has anyone told you that you snore?	☐ Yes ☐ No	
In the past 7 days, were you sleepy during the daytime?	□None □Some □Alot	
On how many of the last 7 days did you engage in moderate to strenuous exercise (like a brisk walk)?	□0 □1 □2 □3 □4 □5 □6 □7	
On those days that you engage in moderate to strenuous exercise, how many minutes, on average, do you exercise at this level?	minutes	
Psychosocial risks – Depression / Stress / So	ocial isolation / Personal loss / Anxiety / Pain & fatigue	/ Behavioral risks
Over the past 2 weeks, how often have you felt down, depressed, or hopeless?	☐ Not at all ☐ Several days ☐ More days than not ☐ Nearly every day	If answer is anything other than "not at all" provider needs to perform PHQ-9 (see page 10)
Over the past 2 weeks, how often have you felt little interest or pleasure in doing things?	□ Not at all □ Several days □ More days than not □ Nearly every day	If answer is anything other than "not at all" provider needs to perform PHQ-9 (see page 10)
Choose the number (0-10) that best describes how much distress you have been experiencing in the past week including today.	□ 0 (no distress) □1 □2 □3 □4 □5 □6 □7 □8 □9	
Do you feel lonely?	☐ Yes ☐ No	
How often do you get the social and emotional support you need?	□None □Some □Alot	
Have you suffered a personal loss or misfortune in the last year? (i.e.: a job loss, disability, divorce, separation, jail term, or death of someone close to you)	☐ No ☐ Yes, one serious loss ☐ Yes, two or more serious losses	
Over past 2 weeks, how often have you felt nervous, anxious, or on edge?	□None □Some □Alot	

Addendum B: Health Risk Assessment (continued)

Psychosocial risks – Depression / Stress / Social isolation / Personal loss / Anxiety / Pain & fatigue / Behavioral risks (continued)				
In the past 7 days, how much pain have you felt?	□None □Some	□Alot		
In the last 30 days, have you smoked cigarettes?	☐Yes ☐No			
In the last 30 days, have you used a smokeless tobacco product	☐ Yes ☐ No			
Sex: How many different sexual partners have you had in the past year?	0 01 02 0]3 or more		
How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?	0 01 02 0]3 or more		
Do you drink alcohol?	# of drinks	oer week		
Do you always fasten your seat belt when you are in a car?	☐ Yes ☐ No			
Do you ever drive after drinking, or ride with a driver who has been drinking?	☐ Yes ☐ No			
Home safety				
Is there anything in your home that makes moving around difficult?	☐ Yes ☐ No			
Are emergency numbers kept by the phone and regularly updated?	☐ Yes ☐ No			
Is there a friend, relative or neighbor who could help you for a few days, if necessary?	☐ Yes ☐ No			
Do you smoke in bed?	☐Yes ☐No			
Do you have smoke alarms in working order?	☐Yes ☐No			
Patient priorities				
Which of the previously discussed health topics is the most important one to talk to your doctor about today?	Which one(s)?			
Do you wish to discuss any end of life issues during this visit?	☐ Yes ☐ No			
Provider information				
Print provider name:		Group name:		
Provider ID:		Tax ID number:		
Provider address:		City, state, zip:		
Provider signature:				
Check one MD DO NP PA Other		Date:		

Addendum B: Health Risk Assessment (continued)

PHQ-9 (To be completed if patient answered on page 8)	d anything exce	ept "not at all"	to the screening questic	ns	Scoring (0=0, 1=1, etc.)
Little interest or pleasure in doing things: [0 = not at all][1 = several days][2 = more than 7 days][3 = nearly every day]					
Feeling down, depressed, or hopeless: [0 = not at all][1 = several days][2 = more than 7 days][3 = nearly every day]					
Trouble falling or staying asleep, or sleeping t [0 = not at all][1 = several days][2 = more than		early every da	y]		
Feeling tired or having little energy: [0 = not at all][1 = several days][2 = more the	nan 7 days][3 =	nearly every o	day]		
Poor appetite or overeating: [0 = not at all][1 = several days][2 = more th	nan 7 days][3 =	nearly every o	day]		
Feeling bad about yourself: or that you are a $[0 = \text{not at all }][1 = \text{several days }][2 = \text{more the several days }]$		-	-		
Trouble concentrating on things, such as rea [0 = not at all][1 = several days][2 = more th					
Moving or speaking so slowly that other peo being fidgety or restless that you have been [0 = not at all][1 = several days][2 = more th	moving around	d a lot more th	ian usual:		
Thoughts that you would be better off dead $[0 = not at all][1 = several days][2 = more the$			-		
Biometric assessment					
Height, weight, BMI (body mass index)	HT	WT	BMI		
Systolic/diastolic BP / blood lipids	HDL	LDL	total cholesterol .		trig
Blood glucose					
Physician notes and summary comments					
Significant health risks and plans	Risk			Plan	
Current additional providers and suppliers involved in care	Name			Туре	
Schedule for health screening	Procedure			Freque	2007
Scriedule for fleatur screening	Procedure			riequei	TICY
Further counseling provided					

Addendum C

Medicare Wellness Visit Preventive Screening Schedule

Patient's Name: _____ Date of Exam: ____ Patient's DOB: ____

Preventive Services (Frequency)	Who is Covered	Date Previously Tested	Optimal Screening Date
Bone Mass Measurement (every 24 months)	Medicare patients at risk for developing osteoporosis	Date / results	If scheduled, when and where, if patient declines or what discussion was
Cardiovascular Screening Blood Tests (every five years)	All asymptomatic Medicare patients (12-hour fast required)	Lipid panel, date, total cholesterol value	Per provider Can look in EHR
Colorectal Cancer Screening (recommended for 50-75 years) Screening colonoscopy (every 24 months at high risk – G0105; every 10 years not at high risk – G0121) Cologuard multi-target stool DNA (9s DNA) test (every three years) Flexible sigmoidoscopy (every four years, or once every 10 years after a screening colonoscopy) Fecal occult blood test (annually)	 Screening colonoscopy – those at high risk, beginning at age 50 (colonoscopy is the gold standard for screenings) Medicare coverage at most every 24 months Cologuard for ages 50-75, but patient must have NO colon cancer risk factors or symptoms. Should be the 2nd option if patient declines colonoscopy/flex sigmoid 	What screening performed, date, results and when to repeat	Date to repeat, discussion of options, what they decided: schedule or declined, can mark no further screenings due to age as well Call to get report if not on record if possible
Diabetes Screenings (two screening tests per year for patient diagnosed with prediabetes; one screening per year if previously tested but not diagnosed with prediabetes or if never tested) AIC 7.0 -9.0 % 3045F or AIC < 7.0% 3044F	Medicare patients with risk factors for diabetes or if never tested or previously tested with prediabetes	Glucose value / date Alc value / date	Six months if diabetic or prediabetic One year if normal
Hepatitis C Screening (one-time screening)	All adults ages 18-79 years	Date / results	UTD or due
Glaucoma Screening (annually for high-risk patients) Include name of optometrist or clinic if known	Patients with diabetes mellitus, family history of glaucoma, African-Americans age 50+, or Hispanic-Americans age 65+	Date (month/year, at a minimum) / results Family history of glaucoma? Pt report acceptable	Yearly for diabetics, document how often / when due, call to get report if diabetic
Prostate Cancer Screening (annually)	Need individualized discussion based on risk, family history and patient preference.	PSA level / date	Prostate specific antigen test, if determined by provider
Screening Mammography (annually)	 One-time screening age 35-40 for baseline Annually age 40 and over Minimum recommendation is every two years for age 50-74 	Date / results	Date due Call to get results if recent
Smoking Cessation (at every visit) document cessation discussion Counseling documented 4004F or non-user 1036F	Medicare patients who use tobacco, regardless of whether they exhibit signs or symptoms of tobacco-related disease	If smoker, document discussed smoking cessation and if wants information or not	If non-smoker, can put line through, write N/A or nonsmoker; if previous smoker put age or date quit
Seasonal Influenza Vaccine (once per flu season) Administered G8482 or declined G8483	All Medicare patients	Date (can be pt report, need month and year)	Yearly
Pneumococcal Vaccines One dose of PCV13 and PPSV23 should be given at least one year apart (give PCV13 first) Patients with previous PPSV23: do PCV13 at least 12 months after PPSV23 administration Admin/previously received 4040F	 If vaccination history is unknown, document unknown history in chart and treat patient as if no pneumococcal vaccines have been given After the first two doses, additional pneumococcal vaccinations may be provided based on risk if at least five years have passed since previous dose 	Date / which was completed	Put when due and which one due or UTD, can also put not age 65 if applicable

Addendum C: Medicare Wellness Visit Preventive Screening Schedule (continued)

Preventive Services (Frequency)	Who is Covered	Date Previously Tested	Optimal Screening Date
 Shingrix (Zoster Vaccine) Two doses given two to six months apart, age 50+ Patients with previous Zostavax, give Shingrix at least two months from previous Zostavax administration (both doses of Shingrix recommended) 	Part D coverage only (given at pharmacy) Send prescription to patient's preferred pharmacy	Date / which one completed	Discuss Shingrix if patient has not had
Alcohol Misuse Screening and Counseling (annually or for those with positive screening 4x a year. Must be completed by physician or APC)	 All Medicare beneficiaries are eligible for alcohol screening G0442 Medicare patients who screen positive are eligible for behavioral counseling for alcohol misuse G0443 4x a year 	You can document what they drink if they do, however we cannot bill for this	
Diabetes Self-Management Training (up to 10 hours of initial training within a continuous 12 month period; subsequent years up to two hours of follow-up training each year after initial year)	Medicare beneficiaries who are diagnosed with diabetes.	They can have this yearly, discuss with diabetic patients what it is and offer if they want. If ordering make sure on form to document any impairments they may have, hearing mobility, understanding, etc.	Document if declines or wants, complete referral form if they want
Lung Cancer Screening Counseling and annual screening for lung cancer with low-dose computed tomography (Requires a shared decision-making discussion with patient's PCP and the discussion MUST be documented in EHR) Use procedure code G0297 and diagnosis code Z87.891	Requirements: • Must be age 55-77 • Be asymptomatic of lung cancer • Have at least a 30-pack/year history of smoking (one pack equals 20 cigarettes) number of years X packs smoked per day • Must be a current smoker or have quit smoking within the last 15 years	Date / results document years smoked and when they quit	When due, if declined, want to schedule or non-smoker
Ultrasound Screening for Abdominal Aortic Aneurysm (AAA) (once in a lifetime)	Requirements: No previous screening under Medicare Must have one of the two risk factors: Family history of AAA Men age 65-75 who smoked at least 100 cigarettes in lifetime	Date / result If had echo or other testing, document that If had echo but never AAA and qualifies, can still have specific AAA screening done	When due, family history, smoking history, patient declines or wants to schedule
Provider Signature:			Date:
Nurse Signature:	Date:		

Addendum D

Adult Preventive Health Care Schedule: Recommendations from the USPSTF (as of August 16, 2019)

To be used in conjunction with USPSTF recommendation statements for additional details (see tables and references at https://www.aafp.org/afp/PHCS)

Only grade A/B recommendations are shown

Age 18 21 24 25 35 40 45 50 55 59 65 70 74 75 80 **USPSTF** screening recommendations (B) Alcohol misuse1 Depression² (B) (A) Hypertension³ Obesity/weight loss⁴ (B) if BMI 30 kg per m² or greater Tobacco use and cessation⁵ HIV infection⁶ (A) (A) if at increased risk Hepatitis B virus infection⁷ (B) if at increased risk Syphilis8 (A) if at increased risk (B) if at increased risk Tuberculosis9 BRCA gene risk assessment¹⁰ (B) if appropriate personal or family history of BRCA-related cancer or ancestry Chlamydia and gonorrhea¹¹ (B) if sexually active (B) if at increased risk (B) women of childbearing age Intimate partner violence¹² Cervical cancer¹³ (A) See p. 3 for test options and screening intervals Abnormal glucose/type 2 diabetes mellitus¹⁴ (B) if overweight or obese Hepatitis C virus infection15 (B) if at high risk (B) birth years 1945-1965 (B) if at high risk Colorectal cancer¹⁶ Breast cancer¹⁷ (B) biennial screening Lung cancer¹⁸ (B) if 30-pack-year history and current or former smoker (quit in past 15 years) Osteoporosis19 (B) if postmenopausal and elevated risk Abdominal aortic aneurysm²⁰ (B) if an "ever smoker" **USPSTF** preventive therapies recommendations HIV preexposure prophylaxis²¹ (A) if at high risk of HIV infection Primary prevention of breast cancer²² (B) if at increased risk and only after shared decision-making Folic acid supplementation²³ (A) if capable of conceiving Statins for primary prevention of CVD²⁴ (B) see criteria on p. 4 Aspirin for primary prevention of CVD and (B) if $\geq 10\%$ colorectal cancer²⁵ 10-year CVD risk Fall prevention in community-dwelling (B) exercise interventions if at older adults²⁶ increased fall risk **USPSTF** counseling recommendations Sexually transmitted infection prevention²⁷ (B) if at increased risk (B) if overweight or obese and with additional CVD risk Diet/activity for CVD prevention²⁸ Skin cancer prevention²⁹ (B) if fair skinned Legend Normal risk With specific risk factor Recommendation grades A Recommended (likely significant benefit) Recommendation for men and women Recommendation for men only Recommended (likely moderate benefit) Recommendation for women only Do not use routinely (benefit is likely small) Recommended against (likely harm or no benefit) Insufficient evidence to recommend for or against

BMI = body mass index; CVD = cardiovascular disease; USPSTF = U.S. Preventive Services Task Force. Visual adaptation from recommendation statements by Swenson PF, Lindberg C, Carrilo C, and Clutter J.

HIV RISK FACTORS

IV drug use Men who have sex with men

Other STI

Requesting STI testing Sex exchanged for drugs or money

Sex with individuals who are IV drug users, bisexual, or HIV positive

Unprotected sex, including anal intercourse

Patients in whom to consider PrEP:

Sexually active men who have sex with men who have any of the following:

Sexual relationship with serodiscordant partner Inconsistent use of condoms during anal sex

Syphilis, gonorrhea, or chlamydia infection in last six months Sexually active heterosexual patients with any of the following:

Sexual relationship with serodiscordant partner Inconsistent use of condoms with high-risk partner Syphilis or gonorrhea infection in last six months

Injection drug users with any of the following:

Shared drug-injection equipment

Risks of infection through sex (see above)

IV = intravenous; PrEP = preexposure prophylaxis; STI = sexually transmitted infection.

HEPATITIS B INFECTION RISK FACTORS

HIV infection Infected sex partner Intravenous drug use Living with an infected individual

Men who have sex with men Origin from regions* with prevalence ≥ 2%

U.S.-born children of immigrants from regions* with prevalence ≥ 8%, if unvaccinated

*Risk of regions can be found at http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr5708a1.htm

SYPHILIS RISK FACTORS

High-risk sexual behaviors Men who have sex with men Incarceration Sex exchanged for money for drugs Local prevalence

TUBERCULOSIS RISK FACTORS

Health professionals* Prisoners, including former Homelessness, including former Residents of high-risk regions, including former Immunosuppression*

*Evidence for screening not reviewed by the USPSTF because this is standard practice in public health and standard of care for patients with immunosuppression, respectively.

CHLAMYDIA AND GONORRHEA RISK FACTORS

New or multiple sex partners Other STI, including history

of STI

Partner with STI Partners who have multiple

sex partners

Sex exchanged for drugs or

money

Sexually active adolescents

Unprotected sex or inconsistent condom use

STI = sexually transmitted infection.

CARDIOVASCULAR DISEASE RISK FACTORS

Diabetes mellitus Metabolic syndrome

Dyslipidemia Obesity Family history Tobacco use

Hypertension

HEPATITIS C INFECTION RISK FACTORS

Blood transfusion before 1992 Chronic hemodialysis

High-risk sexual behaviors Incarceration

Intravenous or intranasal

drua use

Maternal infection (concern for vertical transmission) Unregulated tattoo

BREAST CANCER RISK FACTORS

Consider use of a risk-assessment model for patients with a history of biopsy or positive family history

SEXUALLY TRANSMITTED INFECTION RISK FACTORS

Similar to those risk factors listed previously for sexually transmitted infections; consider local and population-based prevalence in individual risk assessment

Adult Preventive Health Care Schedule: Recommendations from the USPSTF

Grade A/B Recommendations (with Associated Grade C/D/I Recommendations):

Alcohol misuse screening1

(B) Screen adults and provide brief behavioral interventions for risky alcohol use

Depression screening²

(B) Screen adults with systems for evaluation and management

Hypertension screening³

(A) Screen adults; exclude white coat hypertension before starting therapy

Obesity/weight loss screening4

(B) Refer obese adults to intensive behavioral interventions for weight loss

Tobacco use and cessation screening⁵

- (A) Screen adults and provide behavior therapy and U.S. Food and Drug Administration-approved intervention therapy for cessation
- (I) IETRFOA electronic nicotine delivery systems for tobacco cessation

HIV infection screening⁶

- (A) Screen individuals 15 to 65 years of age
- (A) Screen older and younger persons who are at increased risk

Hepatitis B virus infection screening⁷

(B) Screen adolescents and adults at high risk

Syphilis screening8

(A) Screen individuals at increased risk

Tuberculosis screening9

(B) Screen individuals at increased risk

BRCA-related cancer risk assessment/screening10

- (B) Use a familial risk assessment tool (evaluated assessment tools listed in full text) in women with either:
 - Personal or family history of breast, ovarian, tubal, or peritoneal
 - · Ashkenazi Jewish ancestry (i.e., ancestry with increased risk of

For positive risk tools, offer genetic counseling and genetic testing, if

(D) Recommend against screening for patients without appropriate family history, personal history, or ancestry

Chlamydia and gonorrhea screening¹¹

- (B) Screen sexually active women 24 years and younger, and women at increased risk who are 25 years and older
- (I) IETRFOA screening sexually active males

Intimate partner violence screening¹²

- (B) Screen women of childbearing age and refer to appropriate services
- (I) IETRFOA screening all vulnerable and older adults for abuse or neglect

Cervical cancer screening¹³

(A) Screen women

- Age 21 to 29 every three years with cytology alone
- Frequency of screening may increase to every five years for women age 30 to 65 with cytology and high-risk human papillomavirus cotesting or high-risk human papillomavirus testing alone

- (D) Recommend against screening in women
 - Age 20 years and younger
 - Older than 65 years if adequately screened previously and no increased risk of cervical cancer
 - With hysterectomy (including cervix) without history of cervical intraepithelial neoplasia grade 2 or 3 or cervical cancer
 - Younger than 30 years with human papillomavirus testing alone or in combination with cytology

Abnormal glucose and type 2 diabetes mellitus screening¹⁴

(B) Screen overweight or obese adults 40 to 70 years of age and refer patients with abnormal glucose levels for intensive counseling for healthy diet and exercise

Hepatitis C virus infection screening¹⁵

- (B) Offer one-time screening of patients born between 1945 and 1965
- (B) Screen patients at high risk

Colorectal cancer screening¹⁶

- (A) Screen patients 50 to 75 years of age with fecal occult blood (or immunochemical) test, sigmoidoscopy, colonoscopy, computed tomography colonography, or multitargeted stool DNA test
- (C) Recommend against routine screening of patients 76 to 85 years of age

Breast cancer screening¹⁷

- (B) Biennial screening mammography in women 50 to 74 years of age
- (C) Screening is an individualized decision for women 40 to 49 years of age
- - Mammography after 75 years of age
 - Screening with digital breast tomosynthesis
 - Adjunctive screening in women with dense breast tissue and negative screening mammogram

Lung cancer screening¹⁸

(B) Screen annually with low-dose computed tomography for individuals 55 to 80 years of age with a 30-pack-year history who currently smoke or quit within the past 15 years; consider overall health in decision to screen

Osteoporosis screening¹⁹

- (B) Screen women 65 years and older
- (B) Screen postmenopausal women if increased fracture risk shown with an osteoporosis risk tool (e.g., 8.4% in 10 years by U.S. FRAX tool)
- (I) IETRFOA screening men

Abdominal aortic aneurysm screening²⁰

- (B) Screen men 65 to 75 years of age who ever smoked (100 or greater lifetime cigarettes) with one-time abdominal aortic aneurysm ultrasonography
- (C) Recommend selective screening of men 65 to 75 years who have never
- (I) IETRFOA women 65 to 75 years of age who ever smoked
- (D) Recommend against routine screening in women 65 to 75 years who have never smoked

HIV prevention with PrEP²¹

(A) Offer PrEP to persons at high risk of infection. See original text for considerations in patient selection.

continues

CHD = coronary heart disease; CVD = cardiovascular disease; FRAX = Fracture Risk Assessment; IETRFOA = insufficient evidence to recommend for or against; PrEP = preexposure prophylaxis; USPSTF = U.S. Preventive Services Task Force.

Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

Grade A/B Recommendations (with Associated Grade C/D/I Recommendations): (continued)

Primary prevention of breast cancer²²

- (B) Recommend shared decision-making for medications (such as tamoxifen and raloxifene) that reduce risk of breast cancer in women at increased risk
- (D) Recommend against routine use if no increased risk

Folic acid supplementation²³

(A) 0.4 to 0.8 mg daily for women capable of conceiving

Statins for primary prevention of CVD²⁴

- (B) Recommend low- to moderate-dose statin therapy in patients meeting all three criteria:
 - (1) 40 to 75 years of age
 - (2) Dyslipidemia, diabetes, hypertension, or smoker
 - (3) 10-year CVD risk of 10% or greater
- (C) Consider low- to moderate-dose statin therapy in appropriate candidates meeting the first two criteria but with a 10-year CVD risk of 7.5% to 10%
- (I) IETRFOA initiating statin therapy after 75 years of age for primary prevention

Aspirin for primary prevention of CVD and colorectal cancer²⁵

- (B) Recommend low-dose aspirin for patients 50 to 59 years of age with a 10-year CVD risk of 10% or greater, appropriate bleeding risk, and life expectancy of at least 10 years
- (C) Recommend individualized decision-making for patients 60 to 69 years of age who meet the same criteria
- (I) IETRFOA low-dose aspirin for patients younger than 50 years or 70 years or older

Fall prevention in community-dwelling older adults²⁶

- (B) Recommend exercise interventions for individuals 65 years and older at increased risk of falls
- (C) Recommend multifactorial interventions for appropriate individuals 65 years and older; see Clinical Considerations in original recommendation statement for patient selection
- (D) Recommend against vitamin D supplementation for fall prevention

Counseling to prevent sexually transmitted infection²⁷

(B) Recommend counseling to prevent sexually transmitted infection for adolescents and adults at increased risk

Counseling to promote healthy diet and physical activity 28

(B) Recommend that overweight or obese patients with other CVD risk factor(s) be offered or referred for intensive behavioral counseling

Counseling for skin cancer prevention²⁹

- (B) Recommend counseling fair-skinned patients six months to 24 years of age about minimizing ultraviolet radiation
- (C) Recommend selectively counseling fair-skinned patients older than 24 years about minimizing exposure to ultraviolet radiation
- (I) IETRFOA counseling adults about skin self-examination

Grade C Recommendations:

Physical activity and healthy diet counseling to reduce cardiovascular risk in adults without obesity or known CVD risk factors 30

Prostate cancer screening with prostate-specific antigen testing in men 55 to 69 years of age after shared decision-making 31

Grade D Recommendations:

Bacteriuria (asymptomatic) screening in men and nonpregnant women³² Beta carotene or vitamin E supplementation for CVD or cancer risk reduction33

Carotid artery stenosis screening³⁴

CVD screening with resting or exercise electrocardiography in low-risk patients³⁵

Chronic obstructive pulmonary disease screening with spirometry 36

Combined estrogen-progesterone for prevention of chronic conditions or estrogen for the same in patients with hysterectomy³⁷

Genital herpes screening³⁸

Ovarian cancer screening³⁹

Pancreatic cancer screening⁴⁰

Prostate cancer screening with prostate-specific antigen testing in men 70 years and older31

Testicular cancer screening⁴¹

Thyroid cancer screening⁴²

Vitamin D (\leq 400 IU) and calcium (\leq 1,000 mg) supplementation daily for primary prevention of fracture in postmenopausal women⁴³

Grade I Statements:

Atrial fibrillation screening with electrocardiography⁴⁴

Bladder cancer screening⁴⁵

Celiac disease screening⁴⁶

CVD screening in patients with nontraditional risk factors⁴⁷

CVD screening with resting or exercise electrocardiography in intermediateto high-risk patients35

Chronic kidney disease screening⁴⁸

Cognitive impairment screening in older adults⁴⁹

Gynecologic condition screening with pelvic examination⁵⁰

Hearing loss screening in older adults⁵¹

Illicit drug use screening⁵²

Impaired visual acuity screening in older adults⁵³

Multivitamin, single nutrient, or paired nutrients for CVD or cancer risk reduction (beta carotene and vitamin E, as above)33

Obstructive sleep apnea screening54

Oral cancer screening⁵⁵

Peripheral artery disease and CVD risk screening with ankle-brachial index⁵⁶ Primary open-angle glaucoma screening⁵⁷

Primary prevention of fractures with vitamin D and calcium supplementation (alone or combined; dose unspecified) in men or premenopausal women, and in postmenopausal women with daily dosages > 400 IU of vitamin D and > 1,000 mg of calcium⁴³

Skin cancer screening⁵⁸

Suicide risk screening⁵⁹

Thyroid dysfunction screening⁶⁰

Vitamin D deficiency screening in community-dwelling nonpregnant adults⁶¹

CHD = coronary heart disease; CVD = cardiovascular disease; IETRFOA = insufficient evidence to recommend for or against; USPSTF = U.S. Preventive Services Task Force.

Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

REFERENCES

- 1. U.S. Preventive Services Task Force. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(18): 1899-1909
- 2. Siu AL. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(4):380-387.
- 3. Siu AL. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med. 2015;163(10):778-786.
- 4. U.S. Preventive Services Task Force, Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(11):1163-1171.
- 5. Siu AL. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;16(8):622-634.
- 6. U.S. Preventive Services Task Force. Screening for HIV infection: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;321(23): 2326-2336.
- 7. LeFevre ML. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(1):58-66.
- 8. Bibbins-Domingo K. Screening for syphilis infection in nonpregnant adults and adolescents: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(21):2321-2327.
- 9. Bibbins-Domingo K. Screening for latent tuberculosis infection in adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016; 316(9):962-969.
- 10. U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;322(7):652-665.
- 11. LeFevre ML. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(12): 902-910
- 12. U.S. Preventive Services Task Force. Screening for intimate partner violence, elder abuse, and abuse of vulnerable adults: U.S. Preventive Services Task Force final recommendation statement. JAMA. 2018;320(16):1678-1687
- 13. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(7):674-686.
- 14. Sui AL. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(11):861-868.
- 15. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):
- 16. Bibbins-Domingo K. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in JAMA. 2016;316(5):545]. JAMA. 2016;315(23):2564-2575.
- 17. Siu AL. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(4):279-296.
- 18. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5): 330-338.
- 19. U.S. Preventive Services Task Force. Screening for osteoporosis to prevent fractures: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(24):2521-2531.
- 20. LeFevre ML. Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(4):281-290.
- 21. U.S. Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV infection: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;321(22):2203-2213.
- 22. Moyer VA. Medication for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(10):698-708.

- 23. Bibbins-Domingo K. Folic acid supplementation for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;317(2):183-189.
- 24. Bibbins-Domingo K. Statin use for the primary prevention of cardiovascular disease in adults: U.S. Preventive Services recommendation statement. JAMA. 2016;316(19):1997-2007.
- 25. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(12):836-845
- 26. Grossman DC. Interventions to prevent falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(16):1696-1704.
- 27. LeFevre ML. Behavioral counseling interventions to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(12):894-901
- 28. LeFevre ML. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014:161(8):587-593.
- 29. Grossman DC. Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(11):1134-1142.
- 30. Grossman DC. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without cardiovascular risk factors: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017:318(2):167-174.
- 31. Grossman DC. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913.
- 32. Screening for asymptomatic bacteriuria in adults: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2008;149(1): 43-47
- 33. Moyer VA. Vitamins, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(8):558-564
- 34. LeFevre ML. Screening for asymptomatic carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2015;162(4):323]. Ann Intern Med. 2014;161(5):256-262.
- 35. U.S. Preventive Services Task Force. Screening for cardiovascular disease risk with electrocardiography: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(22):2308-2314.
- 36. Siu AL. Screening for chronic obstructive pulmonary disease: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(13):
- 37. Grossman DC. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;318(22):2224-2233.
- 38. Bibbins-Domingo K. Serologic screening for genital herpes infection: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;316(23): 2525-2530
- 39. Grossman DC. Screening for ovarian cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(6):588-594.
- 40. U.S. Preventive Services Task Force. Screening for pancreatic cancer. U.S. Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322(5):438-444
- 41. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2011;154(7):483-486
- 42. Bibbins-Domingo K. Screening for thyroid cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;317(18):1882-1887.
- 43. Grossman DC. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults; U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(15): 1592-1599

Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

- 44. Curry SJ. Screening for atrial fibrillation with electrocardiography: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(5):
- 45. Moyer VA. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2011;155(6):408]. Ann Intern Med. 2011;155(4):246-251.
- 46. Bibbins-Domingo K. Screening for celiac disease: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;317(12):1252-1257.
- 47. U.S. Preventive Services Task Force. Risk assessment for cardiovascular disease with nontraditional risk factors: U.S. Preventive Services Task Force recommendation statement IAMA 2018:320(3):272-280
- 48. Moyer VA. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(8):567-570.
- 49. Moyer VA. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;
- 50. Bibbins-Domingo K. Screening for gynecologic conditions with pelvic examination: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;317(9):947-953
- 51. Moyer VA. Screening for hearing loss in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(9):655-661.
- 52. Screening for illicit drug use [summary]. U.S. Preventive Services Task Force. 2008. Accessed July 1, 2015. http://www.uspreventiveservicestaskforce.org/ Page/Topic/recommendation-summary/drug-use-illicit-screening

- 53. Siu AL. Screening for impaired visual acuity in older adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(9):908-914.
- 54. Bibbins-Domingo K. Screening for obstructive sleep apnea in adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;317(4): 407-414
- 55. Moyer VA. Screening for oral cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;160(1):55-60.
- 56. U.S. Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(2):
- 57. Moyer VA. Screening for glaucoma: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(7):484-489.
- 58. Bibbins-Domingo K. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;316(4):429-435.
- 59. LeFevre ML. Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014:160(10):719-726.
- 60. LeFevre ML. Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;162(9):641-650.
- 61. LeFevre ML. Screening for vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;162(2): 133-140